Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Avigan Not Yet Filed in Japan, but Govt Still Seeks Approval by Month-End: Kato
May 25, 2020
- Add MSD’s 9-Valent HPV Vaccine to National Immunization Program If Approved: Lawmakers
May 21, 2020
- Label Revisions Ordered for 15 Insulins, Erleada, Faslodex
May 20, 2020
- MHLW Adds Veklury in Updated COVID-19 Treatment Guide
May 20, 2020
- LDP Lawmakers Call for Environment to Facilitate Vaccine Development
May 20, 2020
- Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
- MHLW Panel to Discuss HIF-PH Inhibitors from GSK, Mitsubishi Tanabe on May 29
May 19, 2020
- MHLW Panel to Discuss Orphan Status for 5 Cell and Gene Products
May 19, 2020
- Health Ministers of Japan, China, South Korea Commit to Support WHO on COVID-19, Timely Share Info
May 19, 2020
- Govt Won't Require Fujifilm-Sponsored Trial Data to Approve Avigan for COVID-19: Abe
May 18, 2020
- Novartis’ Tabrecta, Enerzair Up for MHLW Panel Review on May 28
May 15, 2020
- Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
- Japan Poised to Quickly Approve Futhan, Actemra, Ivermectin for COVID-19 If Effective: Abe
May 15, 2020
- 400,000 Antigen Test Kits for COVID-19 to Be Supplied by End of May: Health Minister
May 15, 2020
- Suspected COVID-19 Cases to First Receive Antigen Test, Followed by PCR Test if Result is Negative: Suga
May 15, 2020
- COVID-19 Vaccines Too Could Be Filed without Clinical Trial Data: Official
May 15, 2020
- MHLW Urging Novartis to Ensure Speedy Zolgensma Supplies: Sr. Vice Minister
May 15, 2020
- Coefficients for Cost-Based Pricing Formula Updated: Chuikyo
May 15, 2020
- Chuikyo Members Frown on Zolgensma’s Sakigake Premium; Topic Up for 2022 Pricing Debate
May 14, 2020
- MHLW to Accept Applications for COVID-19 Treatments Without Clinical Trial Data; Avigan, Alvesco, Futhan Might Be Eligible
May 14, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…